Clairity has received FDA de novo authorization for Clarity Breast, an AI tool that predicts five-year breast cancer risk from screening mammograms.
Key Details
- 1Clairity Breast predicts future breast cancer risk using AI analysis of 2D screening mammograms.
- 2FDA de novo authorization has been granted for the software platform.
- 3The AI model was trained on 450,000+ mammograms and validated on 77,000 exams with five-year follow-up data.
- 4Unlike CAD tools, the software provides a risk percentage for patients rather than assisting real-time interpretation.
- 5Models were developed for diverse populations, addressing historic limitations in risk prediction for non-European ancestry.
- 6Currently available for Hologic mammography systems, with future plans for multivendor and 3D support.
Why It Matters
This represents a significant advance in leveraging mammogram images beyond immediate diagnosis, opening new avenues for personalized risk assessment in breast imaging. The FDA clearance and focus on diversity in model training mark meaningful steps toward broader clinical adoption and equity.
Source
AuntMinnie
Related News
•Radiology Business
GE HealthCare and RadNet Expand Global AI Mammography Partnership
GE HealthCare and RadNet are extending their partnership globally to offer AI-enhanced mammography systems.
•Radiology Business
NCCN Endorses AI Risk Tools for Breast Cancer Screening
NCCN's 2026 guidelines recommend routine integration of AI-based 5-year breast cancer risk prediction from mammograms.
•AuntMinnie
FDA Rejects Petition to Exempt Radiology AI Devices from 510(k) Review
FDA denies a petition to exempt certain radiology AI software from 510(k) review, stressing ongoing regulatory oversight.